Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Simon Diallo

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|December 19, 2022
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokinesNouf Alluqmani, Anna Jirovec, Zaid Taha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree modelJean-Simon Diallo, Abdulhadi Aldejmah, Abdelali Filali Mouhim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemiaDavid P Conrad, Jovian Tsang, Meaghan Maclean, et al.
Scientific Reports|November 16, 2024
High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activityBoaz Wong, Rayanna Birtch, Anabel Bergeron, et al.
Breast Cancer Research : BCR|August 10, 2016
Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatmentMarie-Claude Bourgeois-Daigneault, Lauren Elizabeth St-Germain, Dominic Guy Roy, et al.
Scientific Reports|January 7, 2026
Lipidomic profiling of influenza A virus production in MDCK cells towards targeted clone selectionJocelyn A Menard, Tilia Zinnecker, Elena Godbout, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyByram W Bridle, Lan Chen, Chantal G Lemay, et al.
Molecular Cancer Therapeutics|March 10, 2025
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian CancerAlison O Cudmore, Galaxia M Rodriguez, Vincent Maranda, et al.
International Journal of Cancer|June 2, 2017
Oncolytic Maraba Virus MG1 as a Treatment for SarcomaFabrice Le Boeuf, Mohammed Selman, Hwan Hee Son, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 28, 2017
Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium CompoundsMohammed Selman, Christopher Rousso, Anabel Bergeron, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|December 19, 2022
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokinesNouf Alluqmani, Anna Jirovec, Zaid Taha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree modelJean-Simon Diallo, Abdulhadi Aldejmah, Abdelali Filali Mouhim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemiaDavid P Conrad, Jovian Tsang, Meaghan Maclean, et al.
Scientific Reports|November 16, 2024
High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activityBoaz Wong, Rayanna Birtch, Anabel Bergeron, et al.
Breast Cancer Research : BCR|August 10, 2016
Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatmentMarie-Claude Bourgeois-Daigneault, Lauren Elizabeth St-Germain, Dominic Guy Roy, et al.
Scientific Reports|January 7, 2026
Lipidomic profiling of influenza A virus production in MDCK cells towards targeted clone selectionJocelyn A Menard, Tilia Zinnecker, Elena Godbout, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyByram W Bridle, Lan Chen, Chantal G Lemay, et al.
Molecular Cancer Therapeutics|March 10, 2025
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian CancerAlison O Cudmore, Galaxia M Rodriguez, Vincent Maranda, et al.
International Journal of Cancer|June 2, 2017
Oncolytic Maraba Virus MG1 as a Treatment for SarcomaFabrice Le Boeuf, Mohammed Selman, Hwan Hee Son, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 28, 2017
Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium CompoundsMohammed Selman, Christopher Rousso, Anabel Bergeron, et al.
Pageof 10